Otsuka Holdings Co (JP:4578) has released an update.
Otsuka Holdings Co. has reported positive interim results from their Phase 3 trial of sibeprenlimab, a promising treatment for immunoglobulin A nephropathy in adults. The trial demonstrated a significant reduction in urine protein levels and maintained a favorable safety profile, paving the way for a potential accelerated approval submission to the FDA. Final results are anticipated in early 2026.
For further insights into JP:4578 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
